Table 1 Demographic features, clinical and laboratory manifestations and treatments in152 patients with SLE
Value | |
|---|---|
Clinical manifestations – N (%) | |
Skin involvement | 115 (75.7) |
Serositis | 31 (20.4) |
Hematological manifestations | 99 (65.1) |
Neuropsychiatric involvement | 15 (9.9) |
Renal involvement | 33 (21.7) |
Laboratory manifestations – N (%) | |
Anti-dsDNA | 114 (78.9) |
Anti-Sm | 28 (18.4) |
Anti-SSA | 62 (40.8) |
Anti-SSB | 35 (23.0) |
Anti-RNP | 24 (15.8) |
Anti-cardiolipin IgG/IgM | 44 (28.9) |
Anti-β2GPI IgG/IgM | 38 (25.0) |
Lupus anticoagulant | 39 (25.6) |
Low C3/C4 levels | 81 (53.3) |
Treatments – N (%) | |
Glucocorticoids | 140 (92.1) |
Hydroxychloroquine | 144 (94.7) |
Cyclosporine A | 34 (22.4) |
Methotrexate | 59 (38.8) |
Cyclophosphamide | 6 (3.9) |
Mycophenolate mofetil | 43 (28.3) |
Azathioprine | 29 (19.1) |
Rituximab | 4 (2.6) |
Belimumab | 9 (5.9) |